PHAT
Phathom Pharmaceuticals, Inc.
Price Chart
Latest Quote
$10.90
+0.02 (+0.18%)
Current Price
| Previous Close | $10.88 |
| Open | $10.86 |
| Day High | $11.07 |
| Day Low | $10.73 |
| Volume | 328,623 |
Stock Information
| Shares Outstanding | 79.76M |
| Total Debt | $547.22M |
| Cash Equivalents | $180.90M |
| Revenue | $204.89M |
| Net Income | $-157.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $869.34M |
| EPS (TTM) | $-2.09 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.23B |
| Sales | $204.89M |
| Income | $-157.30M |
| Book/sh | $-4.24 |
| Cash/sh | $2.27 |
| Employees | 371 |
Financial Ratios
| Quick Ratio | 2.09 |
| Current Ratio | 2.21 |
Returns & Margins
| ROA | -20.15% |
| Gross Margin | 84.93% |
| Operating Margin | -26.55% |
| Profit Margin | -76.77% |
Ownership
| Insider Ownership | 4.73% |
| Institutional Ownership | 89.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.57 |
| P/S | 4.24 |
| P/B | -2.57 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $23.70 |
Technical Indicators
| SMA20 | $10.31 |
| SMA50 | $11.47 |
| SMA200 | $12.76 |
| RSI | 73.45 |
| ATR | 0.6268 |
| Shares Float | 60.34M |
| Short Float | 13.67% |
| Short Ratio | 7.49 |
| Volatility | 0.51 |
| Rel Volume | 0.31 |
Performance History
| Week | +5.11% |
| Month | -8.17% |
| Quarter | -2.77% |
| 6 Months | -29.04% |
| YTD | -30.62% |
| Year | +0.00% |
| 3 Years | -14.64% |
| 5 Years | -68.44% |
| 10 Years | -55.69% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $10.90 | 328,623 |
| 2026-06-18 | $10.88 | 1,102,000 |
| 2026-06-17 | $11.00 | 860,700 |
| 2026-06-16 | $10.43 | 749,500 |
| 2026-06-15 | $10.71 | 692,100 |
| 2026-06-12 | $10.37 | 554,300 |
| 2026-06-11 | $10.27 | 796,600 |
| 2026-06-10 | $9.82 | 827,400 |
| 2026-06-09 | $9.82 | 796,000 |
| 2026-06-08 | $10.00 | 720,400 |
| 2026-06-05 | $10.13 | 1,157,000 |
| 2026-06-04 | $9.86 | 1,038,100 |
| 2026-06-03 | $10.09 | 2,039,600 |
| 2026-06-02 | $9.65 | 1,864,600 |
| 2026-06-01 | $9.24 | 1,599,200 |
| 2026-05-29 | $9.59 | 1,650,800 |
| 2026-05-28 | $10.32 | 1,708,700 |
| 2026-05-27 | $10.74 | 1,088,400 |
| 2026-05-26 | $11.10 | 834,500 |
| 2026-05-22 | $11.33 | 759,700 |
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
đ° Latest News
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
Simply Wall St. âĸ 2026-05-05T10:12:53Z
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks
Simply Wall St. âĸ 2026-05-03T10:08:30Z
Phathom Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-01T01:41:05Z
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-01T00:48:51Z
Phathom (PHAT) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-04-30T21:16:13Z
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-04-30T12:30:12Z
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return
Simply Wall St. âĸ 2026-04-17T04:29:33Z
Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
24/7 Wall St. âĸ 2026-03-27T15:07:33Z
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
Zacks âĸ 2026-03-25T16:15:00Z
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
Zacks âĸ 2026-03-24T16:44:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $22,599,000 | $7,973,000 | $167,000 | $0 |
| Cost Of Revenue | $22,599,000 | $7,973,000 | $167,000 | $0 |
| Total Revenue | $175,110,000 | $55,252,000 | $682,000 | $0 |
| Operating Revenue | $175,110,000 | $55,252,000 | $682,000 | $0 |
| Expenses | ||||
| Interest Expense | $68,115,000 | $72,009,000 | $41,968,000 | $27,305,000 |
| Total Expenses | $335,096,000 | $332,719,000 | $167,994,000 | $172,440,000 |
| Other Income Expense | $-190,000 | $-8,000 | $-188,000 | $-110,000 |
| Other Non Operating Income Expenses | $-190,000 | $-8,000 | $-188,000 | $-110,000 |
| Net Non Operating Interest Income Expense | $-61,071,000 | $-56,851,000 | $-34,092,000 | $-25,173,000 |
| Interest Expense Non Operating | $68,115,000 | $72,009,000 | $41,968,000 | $27,305,000 |
| Operating Expense | $312,497,000 | $324,746,000 | $167,827,000 | $172,440,000 |
| General And Administrative Expense | - | - | - | $100,999,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Net Interest Income | $-61,071,000 | $-56,851,000 | $-34,092,000 | $-25,173,000 |
| Interest Income | $7,044,000 | $15,158,000 | $7,876,000 | $2,132,000 |
| Normalized Income | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Net Income From Continuing And Discontinued Operation | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Total Operating Income As Reported | $-159,986,000 | $-277,467,000 | $-167,312,000 | $-172,440,000 |
| Net Income Common Stockholders | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Net Income | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Net Income Including Noncontrolling Interests | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Net Income Continuous Operations | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Pretax Income | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Interest Income Non Operating | $7,044,000 | $15,158,000 | $7,876,000 | $2,132,000 |
| Operating Income | $-159,986,000 | $-277,467,000 | $-167,312,000 | $-172,440,000 |
| Gross Profit | $152,511,000 | $47,279,000 | $515,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-3.03 | $-5.29 | $-3.93 | $-5.05 |
| Basic EPS | $-3.03 | $-5.29 | $-3.93 | $-5.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-152,499,000 | $-261,522,000 | $-159,049,000 | $-169,798,000 |
| Reconciled Depreciation | $633,000 | $795,000 | $575,000 | $620,000 |
| EBITDA (Bullshit earnings) | $-152,499,000 | $-261,522,000 | $-159,049,000 | $-169,798,000 |
| EBIT | $-153,132,000 | $-262,317,000 | $-159,624,000 | $-170,418,000 |
| Diluted Average Shares | $72,918,764 | $63,176,210 | $51,289,092 | $39,118,215 |
| Basic Average Shares | $72,918,764 | $63,176,210 | $51,289,092 | $39,118,215 |
| Diluted NI Availto Com Stockholders | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Research And Development | $32,780,000 | $34,082,000 | $49,899,000 | $71,441,000 |
| Selling General And Administration | $279,717,000 | $290,664,000 | $117,928,000 | $100,999,000 |
| Other Gand A | - | - | - | $100,999,000 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-438,169,000 | $-253,580,000 | $-72,759,000 | $-74,814,000 |
| Total Assets | $259,149,000 | $378,318,000 | $413,842,000 | $164,810,000 |
| Total Non Current Assets | $30,177,000 | $18,184,000 | $16,410,000 | $4,298,000 |
| Other Non Current Assets | $26,510,000 | $16,095,000 | $12,789,000 | $804,000 |
| Current Assets | $228,972,000 | $360,134,000 | $397,432,000 | $160,512,000 |
| Other Current Assets | $15,353,000 | $20,866,000 | $13,194,000 | $5,127,000 |
| Inventory | $5,518,000 | $3,208,000 | $1,208,000 | $0 |
| Receivables | $78,129,000 | $38,797,000 | $1,637,000 | $0 |
| Accounts Receivable | $78,129,000 | $38,797,000 | $1,637,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $129,972,000 | $297,263,000 | $381,393,000 | $155,385,000 |
| Cash And Cash Equivalents | $129,972,000 | $297,263,000 | $381,393,000 | $155,385,000 |
| Prepaid Assets | - | - | - | $5,127,000 |
| Debt | ||||
| Net Debt | $79,115,000 | - | - | - |
| Total Debt | $211,800,000 | $201,910,000 | $139,030,000 | $97,070,000 |
| Long Term Debt And Capital Lease Obligation | $211,152,000 | $201,409,000 | $138,304,000 | $96,362,000 |
| Long Term Debt | $209,087,000 | $201,409,000 | $137,842,000 | $95,264,000 |
| Current Debt And Capital Lease Obligation | $648,000 | $501,000 | $726,000 | $708,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $697,318,000 | $631,898,000 | $486,601,000 | $239,624,000 |
| Total Non Current Liabilities Net Minority Interest | $565,274,000 | $546,170,000 | $447,820,000 | $213,387,000 |
| Other Non Current Liabilities | $354,122,000 | $344,761,000 | $309,516,000 | $117,025,000 |
| Current Liabilities | $132,044,000 | $85,728,000 | $38,781,000 | $26,237,000 |
| Other Current Liabilities | $34,749,000 | $19,777,000 | $7,111,000 | - |
| Payables And Accrued Expenses | $81,806,000 | $48,791,000 | $17,626,000 | $17,082,000 |
| Interest Payable | $1,833,000 | $1,711,000 | $1,146,000 | $854,000 |
| Payables | $4,983,000 | $10,507,000 | $12,601,000 | $9,997,000 |
| Accounts Payable | $4,983,000 | $10,507,000 | $12,601,000 | $9,997,000 |
| Equity | ||||
| Common Stock Equity | $-438,169,000 | $-253,580,000 | $-72,759,000 | $-74,814,000 |
| Total Equity Gross Minority Interest | $-438,169,000 | $-253,580,000 | $-72,759,000 | $-74,814,000 |
| Stockholders Equity | $-438,169,000 | $-253,580,000 | $-72,759,000 | $-74,814,000 |
| Retained Earnings | $-1,484,258,000 | $-1,263,011,000 | $-928,685,000 | $-727,093,000 |
| Other | ||||
| Treasury Shares Number | $19 | $19 | $19 | $19 |
| Ordinary Shares Number | $71,419,025 | $68,518,238 | $57,970,044 | $41,468,871 |
| Share Issued | $71,419,044 | $68,518,257 | $57,970,063 | $41,468,890 |
| Tangible Book Value | $-438,169,000 | $-253,580,000 | $-72,759,000 | $-74,814,000 |
| Invested Capital | $-229,082,000 | $-52,171,000 | $65,083,000 | $20,450,000 |
| Working Capital | $96,928,000 | $274,406,000 | $358,651,000 | $134,275,000 |
| Capital Lease Obligations | $2,713,000 | $501,000 | $1,188,000 | $1,806,000 |
| Total Capitalization | $-229,082,000 | $-52,171,000 | $65,083,000 | $20,450,000 |
| Treasury Stock | $0 | $0 | $0 | $0 |
| Additional Paid In Capital | $1,046,083,000 | $1,009,425,000 | $855,921,000 | $652,276,000 |
| Capital Stock | $6,000 | $6,000 | $5,000 | $3,000 |
| Common Stock | $6,000 | $6,000 | $5,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,065,000 | $0 | $462,000 | $1,098,000 |
| Current Capital Lease Obligation | $648,000 | $501,000 | $726,000 | $708,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,841,000 | $16,659,000 | $13,318,000 | $8,447,000 |
| Current Accrued Expenses | $76,823,000 | $38,284,000 | $5,025,000 | $7,085,000 |
| Net PPE | $3,667,000 | $2,089,000 | $3,621,000 | $3,494,000 |
| Accumulated Depreciation | $-3,475,000 | $-2,841,000 | $-2,046,000 | $-1,471,000 |
| Gross PPE | $7,142,000 | $4,930,000 | $5,667,000 | $4,965,000 |
| Leases | $242,000 | $160,000 | $139,000 | $115,000 |
| Other Properties | $1,487,000 | $1,487,000 | $1,487,000 | $2,287,000 |
| Machinery Furniture Equipment | $2,810,000 | $2,670,000 | $2,566,000 | $2,164,000 |
| Buildings And Improvements | $2,603,000 | $613,000 | $1,475,000 | $2,287,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,457,000 | $1,479,000 | $647,000 | - |
| Raw Materials | $4,061,000 | $1,729,000 | $561,000 | - |
| Construction In Progress | - | - | $0 | $399,000 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-167,004,000 | $-266,905,000 | $-139,214,000 | $-147,571,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-166,775,000 | $-266,770,000 | $-137,580,000 | $-146,530,000 |
| Cash Flow From Continuing Operating Activities | $-166,775,000 | $-266,770,000 | $-137,580,000 | $-146,530,000 |
| Investing Activities | ||||
| Capital Expenditure | $-229,000 | $-135,000 | $-1,634,000 | $-1,041,000 |
| Investing Cash Flow | $-229,000 | $-135,000 | $-1,634,000 | $-1,041,000 |
| Cash Flow From Continuing Investing Activities | $-229,000 | $-135,000 | $-1,634,000 | $-1,041,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $121,775,000 | $155,463,000 | $24,596,000 |
| Financing Cash Flow | $-288,000 | $182,774,000 | $367,580,000 | $120,042,000 |
| Cash Flow From Continuing Financing Activities | $-288,000 | $182,774,000 | $367,580,000 | $120,042,000 |
| Net Other Financing Charges | $-1,926,000 | - | $172,675,000 | $95,446,000 |
| Net Common Stock Issuance | $0 | $121,775,000 | $155,463,000 | $24,596,000 |
| Common Stock Issuance | $0 | $121,775,000 | $155,463,000 | $24,596,000 |
| Other | ||||
| Issuance Of Debt | $0 | $59,400,000 | $39,318,000 | $0 |
| Interest Paid Supplemental Data | $21,368,000 | $17,293,000 | $11,133,000 | $7,033,000 |
| End Cash Position | $132,833,000 | $300,125,000 | $384,256,000 | $155,890,000 |
| Beginning Cash Position | $300,125,000 | $384,256,000 | $155,890,000 | $183,419,000 |
| Changes In Cash | $-167,292,000 | $-84,131,000 | $228,366,000 | $-27,529,000 |
| Proceeds From Stock Option Exercised | $1,638,000 | $1,599,000 | $124,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $59,400,000 | $39,318,000 | $0 |
| Net Long Term Debt Issuance | $0 | $59,400,000 | $39,318,000 | $0 |
| Long Term Debt Issuance | $0 | $59,400,000 | $39,318,000 | $0 |
| Net PPE Purchase And Sale | $-229,000 | $-135,000 | $-1,634,000 | $-1,041,000 |
| Purchase Of PPE | $-229,000 | $-135,000 | $-1,634,000 | $-1,041,000 |
| Change In Working Capital | $-12,376,000 | $-15,298,000 | $-13,644,000 | $5,438,000 |
| Change In Other Working Capital | $222,000 | $175,000 | $194,000 | $-238,000 |
| Change In Other Current Assets | $-1,224,000 | $0 | $-1,394,000 | $-118,000 |
| Change In Payables And Accrued Expense | $34,225,000 | $35,501,000 | $6,702,000 | $7,654,000 |
| Change In Accrued Expense | $121,000 | $565,000 | $292,000 | $-1,025,000 |
| Change In Interest Payable | $121,000 | $565,000 | $292,000 | $377,000 |
| Change In Payable | $34,104,000 | $34,936,000 | $6,410,000 | $8,679,000 |
| Change In Account Payable | $34,104,000 | $34,936,000 | $6,410,000 | $8,679,000 |
| Change In Prepaid Assets | $5,513,000 | $-7,672,000 | $-8,067,000 | $-1,860,000 |
| Change In Inventory | $-11,781,000 | $-6,142,000 | $-9,442,000 | $0 |
| Change In Receivables | $-39,331,000 | $-37,160,000 | $-1,637,000 | $0 |
| Changes In Account Receivables | $-39,331,000 | $-37,160,000 | $-1,637,000 | $0 |
| Other Non Cash Items | $37,216,000 | $57,176,000 | $32,056,000 | $21,002,000 |
| Stock Based Compensation | $28,719,000 | $24,047,000 | $45,025,000 | $24,133,000 |
| Provisionand Write Offof Assets | $280,000 | $836,000 | $0 | - |
| Depreciation Amortization Depletion | $633,000 | $795,000 | $575,000 | $620,000 |
| Depreciation And Amortization | $633,000 | $795,000 | $575,000 | $620,000 |
| Net Income From Continuing Operations | $-221,247,000 | $-334,326,000 | $-201,592,000 | $-197,723,000 |
| Repayment Of Debt | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
Fetched: 2026-06-21